One-year real-life results on effect of inravitreal aflibercept in patients with diabetic macular edema switched from ranibizumab
International Journal of Development Research
One-year real-life results on effect of inravitreal aflibercept in patients with diabetic macular edema switched from ranibizumab
Received 19th December, 2020 Received in revised form 24th January, 2021 Accepted 14th February, 2021 Published online 15th March, 2021
Copyright © 2021, Dan Călugăru and Mihai Călugăru. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The authors are commenting on the study entitled :“One-year real-life results on th effect of intravitreal aflibercept in patient with diabetic macular edema switched from ranibizuamab” published by Lukic et al. in Eur J Ophthalmol 2020; Doi: org/101177/1120672120927275. Published online: May 26, 2020, which assessed the visual and optical coherence tomography-derived anatomical outcomes of treatment with intravitreal aflibercept for diabetic macular edema in patients switched from intravitreal ranibizumab. The authors found that there was a significant improvement in visual acuity and in anatomical outcomes in the switched group at 12 months after commencing treatment with aflibercept for diabetic macular edema. However, the validation, extrapolation, and generalizability of this findings can only be validated through statistical analyses including all the missing baseline potential risk factors referred to above by us in addition to the baseline characteristics already evaluated in this study, serving to emphasize the putative biomarkers assessing the visual acuity and anatomical benefits in switching anti-vascular endothelial growth factor agent in diabetic macular edema patients.
